

Research Article

Interrelations between Serum N-Terminal Pro B-Type Natriuretic Peptide (Nt-Probnp) Levels and Early Cardiovascular Risk Factors and Echocardiographic Parameters in Obese Adolescents

Mehmet Boyraz¹, Ozgur Pirgon^{2*}, Bumin Dundar³, Bedir Akyol⁴ and Nezaket Eren⁵

¹Department of Pediatric Endocrinology and Diabetes, Faculty of Medicine, Fatih University, Ankara, Turkey

²Department of Pediatric Endocrinology and Diabetes, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey

³Department of Pediatric Endocrinology and Diabetes, Faculty of Medicine, Katip Celebi University, Izmir, Turkey

⁴Department of Pediatric Cardiology, Sadi Konuk Training and Research Hospital, Istanbul, Turkey

⁵Department of Biochemistry, Sisli Etfal Training and Research Hospital, Istanbul, Turkey

Abstract

Aim

This study aimed to evaluate the associations between the N-Terminal pro B-type Natriuretic Peptide (NT-proBNP) levels and the metabolic, echocardiographic parameters, carotid Intima-Media Thickness (IMT) and Epicardial Adipose Tissue Thickness (EATT) in adolescent obesity.

Materials and methods

The study participants consisted of 138 obese adolescents in the study group and 63 non-obese adolescents as control subjects. All the subjects underwent transthoracic echocardiographic examination for determination of Left Ventricular (LV) systolic function and mass index, myocardial tissue rates, and myocardial performance index. EATT and carotid IMT were also measured during echocardiography. Serum NT-proBNP levels were measured at the time of the evaluation.

*Corresponding author: Ozgur Pirgon, Department of Pediatric Endocrinology and Diabetes, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey, Tel: +90 2462119302; E-mail: ozgurpirgon@gmail.com

Citation: Mehmet B, Ozgur P, Bumin D, Bedir A, Nezaket E (2015) Interrelations between Serum N-Terminal Pro B-Type Natriuretic Peptide (Nt-Probnp) Levels and Early Cardiovascular Risk Factors and Echocardiographic Parameters in Obese Adolescents. J Neonatol Clin Pediatr 2: 005.

Received: August 02, 2014; **Accepted:** January 30, 2015; **Published:** February 06, 2015

Results

The NT-proBNP values averaged 67.2 ± 64.4 pg/ml in mildly-moderately obese and 76.0 ± 49.7 pg/ml in the severely obese group and 44.3 ± 23.3 pg/ml in the control group ($p:0.007$, $p:0.002$, respectively). The average carotid IMT was 0.91 ± 0.23 and 0.88 ± 0.18 mm in the obesity groups and 0.52 ± 0.08 mm in the control group ($p<0.001$), but differences were not observed between obesity groups and the EATT measurements that averaged 7.38 ± 1.76 and 7.42 ± 1.55 mm in the obesity groups and 4.28 ± 0.79 mm in the control group ($p<0.001$). The serum NT-proBNP levels showed positive correlations with LV systolic and diastolic functions, carotid IMT and EATT values especially in severely obese adolescents.

Conclusion

The study showed that serum NT-proBNP levels were higher in mildly-moderately and severely obese adolescents than lean group. NT-proBNP measurement might be useful a marker for predicting atherosclerosis and cardiac dysfunction in obese adolescents.

Keywords: Adolescent obesity; Atherosclerosis; Cardiovascular risk; Echocardiography; N-terminal pro B-type natriuretic peptide

Introduction

Childhood obesity is accompanied with an increased cardiovascular disease risk profile in adulthood [1]. Hypertension, dyslipidemia, cardiomyopathy and coronary heart disease are known as cardiovascular complications of obesity, together with insulin resistance, diabetes mellitus, and sleep apnea, which often accompany with obesity [2,3]. Epidemiological, echocardiographic, and autopsy studies have identified obesity cardiomyopathy as an isolated clinical entity [4-6]. In these studies, elevated Body Mass Index (BMI) is described as a risk factor for Left Ventricular (LV) remodeling and overt heart failure. LV enlargement and eccentric hypertrophy are the most common morphological cardiac abnormalities in obese individuals [5]. Cardiac remodeling depends on the intensity and duration of obesity and the influence of adverse loading conditions [7,8].

Natriuretic peptide signaling may actively influence differential body fat distribution. N-Terminal-pro-Brain Natriuretic Peptide (NT-proBNP) and brain natriuretic peptide are useful for the diagnosis of heart failure, and their high levels in serum and plasma, respectively, are related to wall stress, which is often increased in severe obesity. High brain natriuretic peptide as well as high NT-proBNP are new promising cardiovascular risk markers and have been associated with high blood pressure, and LV hypertrophy [9,10]. These are sensitive markers of cardiac dysfunction and may be useful in the early diagnosis of cardiac loading.

NT-proBNP is extremely reliable due to the high negative predictive value so it is used more frequently than from brain natriuretic peptide [11,12]. Recent findings on the relationship between NT-proBNP and metabolic parameters, morphologic and dynamic cardiac abnormalities in adolescent obesity are still inconsistent and controversial. Therefore, the aim of the present study was to evaluate the associations of serum NT-proBNP levels to cardiovascular risk factors, echocardiographic and metabolic parameters in obese adolescents.

Materials and Methods

Patients

In this study, 138 pubertal obese adolescents (66 girls, 72 boys aged between 116-210 month, mean age 164.9 ± 21 mo) and 63 healthy adolescents (mean age 170.3 ± 27 mo, range 102 - 216 mo) were enrolled and evaluated according to their sex and age between September, 2011 and November, 2012. During this period, the cases admitted to the Pediatric Endocrinology Department of Istanbul Sisli Etfal Research Hospitals with the complaint of obesity were enrolled in the study. The 63 healthy age - and sex - matched adolescents selected to be control subjects were referred for cardiac murmurs detected by auscultation but later proved to be innocent murmurs by clinical and laboratory methods. During pubertal evaluation, Tanner staging was used. Testes size were ≥ 4 ml in males and the Tanner stage of breast development \geq stage II were in females assumed as puberty.

The adolescents receiving treatment for any reason, syndromic ones and patients having either an endocrinological disease or familial dyslipidemia were dismissed from the study. Patients were excluded if they had any systemic disease, including type 1 or type 2 diabetes mellitus, taking medications, or had a condition known to effect insulin action, or insulin secretion (e.g., glucocorticoid therapy, hypothyroidism, Cushing's disease). This study was conducted in accordance with the guidelines proposed in the Helsinki Declaration and was received the approval of Istanbul Sisli Etfal Research Hospitals Ethics Committee on 19 July, 2011. The informed consent form was obtained from the patients or the legal guardians.

Anthropometric variables

Anthropometric measurements were performed in all patients. Height and weight were measured with an empty bladder in postabsorptive conditions. For height measurement, Harpenden stadiometer (sensitive to 0.1 cm) was used, and weight was determined to the nearest 0.1 kg on a standard physician's beam scale with the subject dressed only in light underwear without shoes. BMI was calculated by the weight (kg)/height (m²) formula. To compare BMI for different ages and for both boys and girls, BMI-SDS (Standard Deviation Score) was considered. BMI-SDS was calculated with the Lambda, Mu and Sigma method. The z-score represented as the number of SD above or below the considered population mean value based on standardized tables for children [13]. Obesity was defined as a BMI above 2 SD which corresponds to the 97th adjusted for age and gender. The degree of obesity was determined using BMI-SDS and the cases were divided into two groups according to their SDS. BMI-SDS between 1.65-2.49 and 2.50-2.99 represented as mildly-moderately and severely obesity, respectively [14]. Waist circumference was measured with a non-elastic tape measure. The waist circumference was recorded at the end of expiration and between the midpoint of the last rib and superior iliac crest [15].

Blood pressure

Blood pressure was measured by a mercury sphygmomanometer with an appropriate sleeve according to different ages after at least ten minute rest. We used the National High Blood Pressure Education Program Working Group normal values for children as a reference to evaluate blood pressure measurements [16]. Blood pressure \geq 95th percentile for age, sex and height was accepted as hypertension.

Laboratory analyses

Laboratory parameters of all patients, including glucose, insulin, lipid profiles (triglycerides, total cholesterol, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, and very-low-density lipoprotein-cholesterol) and high-sensitivity C-reactive protein were recorded in the morning after an overnight hunger. The glucose oxidase method was used in the determination of blood glucose levels. Insulin levels were measured using a radioimmunoassay kit (Immunotech kit). Serum lipid profiles were measured using a modular analytical system (Roche/Hitachi). Serum hs-CRP was determined by using particle-enhanced immunoturbidimetry with the latex microparticles sensitized in the duck anti-CRP Immunoglobulin Y (Missouri).

N-Terminal Pro B-Type natriuretic peptide measurements

In both groups, blood samples of 0.5 ml were obtained from the antecubital vein using a heparinized syringe, and serum NT-pro BNP levels were measured by a solid-phase, enzyme-labeled chemiluminescent immunometric assay. Immulite 1000 was supplied by Siemens Medical Solutions Diagnostic (Los Angeles, CA, USA).

Insulin sensitivity measurement

Insulin resistance was analyzed using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) based on the following formula: (fasting insulin mIU/L x fasting glucose mmol/L)/22.5. A HOMA-IR value greater than 3.16 was used to determine the insulin resistance in pubertal patients [17].

Echocardiographic evaluation

Transthoracic echocardiographic examinations were performed by single experienced pediatric cardiologist. Echocardiographic measurements were performed with a ViVid 7 Pro (GE Vingmed Ultrasound, Horten Norway). An electrocardiogram was taken from all subjects. The patients were studied without sedation while they were lying in the left lateral positions. 3 MHz transducers were used in all echocardiographic studies. All possible echocardiographic windows obtained from the different Doppler devices such as two-dimensional, colored, pulsed-wave, continuous-wave, and pulsed-wave tissue were analysed for the subjects lying supine or in the left lateral semirecumbent position. LV systolic functions and LV mass index were assessed using M-mode and 2 D, whereas myocardial tissue rates and Myocardial Performance Indices (MPI) were studied using tissue Doppler methods.

Conventional echocardiography measurements were performed by using recommendation of the American Society of Echocardiography [18]. The LV mass and the LV mass index were calculated by using the method of Woythaler and his colleagues, which is also a modification of the method of Devereux and Reichek [1].

Pulsed-wave tissue Doppler imaging

A pulsed Doppler and tissue Doppler were performed using a 3-MHz transducer. We measured Early (E) and Atrial (A) transmitral maximal flow velocities by pulsed-wave Doppler. Then we calculated the ratio E/A. Tissue Doppler sample volume of 2-5 mm, a Nyquist limit adjusted to a velocity rate of 15 to 20 cm/s and monitor velocity to 100 mm/s. The gain was minimized to allow for a clear tissue signal with minimal background noise. Using the apical four-chamber view, the sample volume was placed at the mitral valve annuli at the LV free wall. Early (E') and late (A') diastolic peak velocities were measured.

The ratio of early and late diastolic annular velocities was calculated. Cardiac time intervals; isovolumic contraction time, isovolumic relaxation time and systolic ejection time were measured. Tissue Doppler derived by MPI was calculated as (isovolumic contraction time + isovolumic relaxation time)/ systolic ejection time. And we also measured E' wave acceleration and deceleration time.

The thickness of the epicardial adipose tissue was measured from the right ventricular free wall in the parasternal long axis view. The epicardial adipose tissue was identified as an echo-free space in the pericardial layers on the two-dimensional echocardiography, and its thickness was measured perpendicularly on the free wall of the right ventricle at end diastole [19,20].

To standardize the set point of measurement between different observers, the aortic annulus was used as the anatomic reference. The measurement was performed at a point on the free wall of the right ventricle along the midline of the ultrasound beam perpendicular to the aortic annulus. The average value from three cardiac cycles was used for the statistical analyses.

Carotid intima-media thickness measurements

Carotid IMT measured by a single radiologist, who was blinded to the clinical and laboratory status of the patients, using high-resolution B-mode ultrasonography (Logiq 7) using a high-resolution linear-array vascular transducer (7 MHz). An optimal 2-dimensional image of the common carotid artery was obtained in which the near and far wall intima-media complex was well visualized. After a 10-minute rest and according to standard guidelines, the M-mode cursor was then placed 1 cm proximal to the beginning of the carotid artery bulb during end-diastole [21]. The measurements from three consecutive beats were averaged and recorded as the carotid IMT [22]. There was no evidence of carotid plaque formation in all obese and control groups.

Statistical analysis

Differences among the study groups were analyzed using student's t test. Correlations were analyzed using Pearson's correlation coefficient. Using multiple regression analyses, correlations were adjusted for age and gender, body composition, metabolic cardiovascular risk factors, hemodynamic cardiovascular risk factors, and subclinical cardiovascular damage, calculating the standardized regression quotient. Only variables with P values <0.10 entered the final multiple regression models, in which we performed by stepwise and backward selection. All p values less than 0.05 were considered statistically significant.

Results

The characteristics of the study population were shown in Table 1. This study investigated 138 obese adolescents and 63 healthy age- and sex-matched control. The obese adolescents were divided into two groups based on BMI-SDS. The three groups did not differ significantly in terms of age (170.3 ± 27.0, 169.6 ± 20.1, 162.1 ± 23.2 mo, respectively) (p>0.05). However, the groups differed significantly in terms of BMI (20.1 ± 1.3, 33.9 ± 9.3, 39.4 ± 4.0 kg/m², respectively) (p:0.001). The obesity and the control groups did not differ significantly according to the heart rate (79 ± 5 vs. 78 ± 7 beats/min; p>0.05) or average hemoglobin value (13.1 ± 1.04 vs. 12.9 ± 1.1 g/dl, p>0.05). However, the average systolic and diastolic blood pressure values differed significantly between the obesity and the control groups (p:0.001) (Table 1).

	Leans	Obese	
		Mild-moderate	Severe
n	63	95	43
Age (mo)	170.3 ± 27.0	169.6 ± 20.1	162.1 ± 23.2
BMI (kg/m ²)	20.1 ± 1.3	33.9 ± 9.3 [‡]	39.4 ± 4.0 ^{†,*}
BMI-SDS	1.2 ± 0.2	2.2 ± 0.2 [‡]	2.7 ± 0.2 [*]
Waist circumference (cm)	67.0 ± 5.8	102.7 ± 8.7 [‡]	112.3 ± 11.1 ^{†,*}
Hip circumference (cm)	91.0 ± 7.6	114.4 ± 8.5 [‡]	124.3 ± 10.0 ^{†,*}
Fasting glucose (mg/dl)	84.5 ± 10.3	90.1 ± 9.3 [‡]	91.6 ± 9.2 [†]
Fasting insulin (mIU/ml)	10.9 ± 2.5	26.6 ± 15.2 [‡]	27.0 ± 11.5 [†]
HOMA-IR	2.2 ± 0.6	5.9 ± 3.9 [‡]	5.7 ± 2.7 [†]
HDL-C (mg/dl)	48.2 ± 16.8	46.1 ± 10.2	45.3 ± 11.3
LDL-C (mg/dl)	80.4 ± 29.2	110.1 ± 142.5 [‡]	100.8 ± 25.3 [†]
Triglycerides (mg/dl)	144.5 ± 37.3	122.8 ± 62.0 [‡]	131.7 ± 59.9 [†]
Total cholesterol (mg/dl)	164.1 ± 36.2	168.9 ± 35.7	174.4 ± 35.0 [†]
NT- proBNP (pg/ml)	44.3 ± 23.3	67.2 ± 64.4 [‡]	76.0 ± 49.7 [†]
High sensitivity CRP (mg/L)	1.7 ± 0.8	1.9 ± 1.1 [†]	2.7 ± 1.0 ^{†,*}
Systolic Blood Pressure (mm Hg)	105.2 ± 11.7	128.0 ± 14.3 [‡]	127.7 ± 23.3 [†]
Diastolic Blood Pressure (mm Hg)	71.8 ± 7.0	83.0 ± 10.3 [‡]	86.7 ± 10.8 [†]
Left ventricular mass index (g/m ²)	62.4 ± 18.2	88.5 ± 23.0 [‡]	87.5 ± 34.8 [†]
Myocardial performance index	0.4 ± 0.1	0.4 ± 0.1	0.5 ± 0.1 ^{†,*}
Carotid intima-media thickness (mm)	0.52 ± 0.08	0.88 ± 0.18 [‡]	0.91 ± 0.23 [†]
Epicardial adipose tissue thickness (mm)	4.28 ± 0.79	7.38 ± 1.76 [‡]	7.42 ± 1.55 [†]

Table 1: Characteristics of leans and obese adolescents.

* p< 0.05 Mild-moderate obese vs. severe obese

‡ p < 0.05 Leans vs. mild-moderate obese

† p < 0.05 Leans vs. severe obese

BMI: Body Mass Index; HDL-C: High Density Lipoprotein Cholesterol; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; LDL-C: Low Density Lipoprotein Cholesterol; NT- proBNP : N-Terminal Pro B-Type Natriuretic Peptide; Values are mean ±SD

The average LV mass index was greater in the mildly-moderately and severely obese group than in the control group (88.5 ± 23, 87.5 ± 34.8 and 62.4 ± 18.2 g/m² respectively, p:0.012), but there was no difference between the groups in obesity (p>0.05).

The average carotid IMT was 0.88 ± 0.18 and 0.91 ± 0.23 mm respectively in the mildly-moderately and severely obese group and 0.52 ± 0.08 mm in the control group (p:0.002). However, significant differences were not observed between obesity groups (p>0.05). The average EATT was 7.38 ± 1.76 and 7.42 ± 1.55 mm respectively in the mildly-moderately and severely obese and 4.28 ± 0.79 mm in the control group (p:0.0032). The mitral valve pulsed-wave Doppler analyses show a statistically significant difference between leans and obese groups in terms of diastolic early wave peak velocity (E'), diastolic late wave peak velocity (A'), (E'/A'), isovolumic relaxation time, average MPI, acceleration time and average deceleration time. The average acceleration time, average deceleration time and average MPI were greater in severe obese group than mild-moderate obese group (p<0.05). The results of the tissue Doppler imaging studies from the mitral annulus for three groups are summarized in Table 2. In the all obese group, there were statistically significant correlations between BMI and LV mass index (r:0.38, p:0.03), MPI (r:0.72, p:0.003

and) carotid IMT (r:0.34, p:0.033) and EATT (r:0.45, p:0.023). Moreover; a statistically significant positive correlation was found between EATT and the carotid IMT (r:0.60, p:0.002).

	Leans	Obese	
		Mild-moderate	Severe
n	63	95	43
Left ventricular systolic function			
Ejection fraction (%)	65.3 ± 3.8	64.6 ± 4.1	64.5 ± 3.7
Fractional shortening (%)	35.4±2.9	35.3 ± 3.2	34.9 ± 2.7
Left ventricular diastolic function			
Diastolic early wave peak velocity (cm/sn)	17.8 ± 2.9	16.8 ± 3.1 [‡]	16.9 ± 3.1 [†]
Diastolic late wave peak velocity (cm/sn)	6.5 ± 1.3	7.3 ± 1.5 [‡]	7.7 ± 1.7 [†]
E/A'	2.8 ± 0.7	2.4 ± 0.6 [‡]	2.3 ± 0.5 [†]
Isovolumic relaxation time (ms)	49.1 ± 8.3	50.7 ± 8.3 [‡]	53.7 ± 10.3 [†]
Acselelration time (ms)	53.9 ± 8.5	52.6 ± 9.0 [‡]	48.6 ± 8.4 ^{†*}
Deceleration time (ms)	74.3 ± 9.6	73.6 ± 9.8 [‡]	66.0 ± 6.0 ^{†*}
Left ventricular systolic and diastolic function			
Myocardial performance index	0.4 ± 0.1	0.4 ± 0.1	0.5 ± 0.1 ^{†*}

Table 2: Left ventricular systolic and diastolic functions of leans and obese cases. Values are mean ±SD.

* p < 0.05 Mild-moderate obese vs. severe obese

‡ p < 0.05 Leans vs. mild-moderate obese

† p < 0.05 Leans vs. severe obese

NT-proBNP measurement in relation to obesity, metabolic and hemodynamic risk factors

The NT-proBNP values averaged 76.0 ± 49.7 pg/ml pg/ml in the severely obese group and 44.3 ± 23.3pg/ml in the control group (p:0.001). However NT- proBNP levels were not different between the obesity groups. (Figure 1). NT-proBNP was positively correlated with BMI (r:0.667, p<0.001), waist circumference (r:0.545, p<0.001), hip circumference (r:0.516, p<0.001), diastolic blood pressure (r:0.598, p<0.001) in the severely obese group (Table 3). After adjusting for age and gender using multiple regression analyses, higher NT-proBNP was associated with higher BMI (β:0.13; p<0.05), higher waist circumference (β:0.12; p<0.05), lower serum triglycerides (β:-0.16; p<0.001), higher serum insulin (β:0.15; p<0.001), and higher diastolic blood pressure (β:0.07; p<0.01).

Nt-proBNP measurement in relation to subclinical cardiovascular damage

The variables correlated to NT-proBNP were LV posterior wall diastolic thickness (r:0.424, p<0.001), interventricular septum diastolic thickness (r:0.495, p<0.001), LV posterior wall systolic thickness (r:0.456, p<0.001), LV posterior wall thickness (r:0.544, p<0.001), ejection fraction (r:0.297, p:0.021), acceleration time (r:0.279, p:0.045), LV mass index (r:0.649, p<0.001), MPI (r:0.288, p:0.042), EATT (r:0.339, p:0.022) and the carotid IMT (r:0.325, p:0.003) in severely obesity (Table 3). After adjusting for age, gender, and metabolic and hemodynamic cardiovascular risk factors, NT-proBNP was correlated to LV ejection fraction (β:0.08; p<0.001), LV mass index (β:0.04; p<0.05) and MPI (β:0.06; p<0.01) in multiple regression analyses.




Figure 1: Comparisons of the plasma N-terminal pro B-type natriuretic peptide levels in leans, mild-moderate and severe obese groups.

NT-proBNP measurement in relation to hypertension

Obese adolescents with normal and elevated systolic and diastolic blood pressures (109.1 ± 9.4 mmHg systolic and 67.3 ± 4.3 mmHg diastolic vs 120.1 ± 11.9 mmHg systolic and 80.5 ± 7.5 mmHg diastolic) were further compared for serum NT-proBNP, LVMI and carotid IMT significant correlations were noted (p<0.05) (Table 4).

Discussion

This cross-sectional study provided the evidence that obese adolescents exhibit increased carotid IMT and EATT measurements and abnormalities of LV structure related to NT-proBNP levels. In addition; the study showed a positive significant association between increased NT-proB levels and increased carotid IMT and EATT.

We found significant differences in NT-proBNP levels among the groups. In children there are a few studies examining the relations between NT-proBNP levels and obesity. In a study, NT-proBNP concentrations were found to be higher in obese children than the control group similar results of our study [23]. Childhood obesity causes to changes in the heart's structure and function and it is associated with cardiovascular risk factors [24]. Starting from childhood, myocardial mass parallels the increase in BMI. It is shown that LV hypertrophy occurs in obesity and that this hypertrophy is associated with an increased risk of cardiovascular diseases [25,26]. In the current study, the LV mass index was higher in the obese group than in the control group. This difference was statistically significant because it is known that LV hypertrophy affects diastolic function negatively. On the other hand, in obese patients with no ventricle hypertrophy, cardiac functions may deteriorate. Moreover, this deterioration may be seen in each ventricle [27,28].

Obesity is an important risk factor for atherosclerotic cardiovascular disease. Neeland IJ et al., demonstrated a significant association between higher levels of natriuretic peptides and adiposity, including decreased visceral and liver fat and increased lower body fat, independent of age, sex, race, and obesity-status [29]. We found that serum NT-proBNP levels were higher in patients with the obesity attributable to straight relationships between serum NT-proBNP and LV mass index, LV ejection fraction and MPI independently of age, gender, and metabolic and hemodynamic cardiovascular risk factors in obese adolescents. Bradham WS et al., [30] reported that in adult patients, insulin resistance is

	Obese			
	Mild-moderate		Severe	
	r	p	r	p
Body composition				
BMI (kg/m ²)	0.484	0.001	0.667	<0.001
BMI-SDS	0.384	0.004	0.667	<0.001
Waist circumference (cm)	0.226	0.04	0.545	<0.001
Hip circumference (cm)	0.315	0.01	0.516	<0.001
Metabolic factors				
Fasting glucose (mg/dl)	0.122	NS	0.135	NS
Fasting insulin (mIU/L)	0.133	NS	0.123	NS
HOMA-IR	0.116	NS	0.084	NS
HDL-Cholesterol (mg/dl)	0.020	NS	0.023	NS
LDL-Cholesterol (mg/dl)	0.114	NS	0.119	NS
Triglyceride (mg/dl)	-0.183	NS	-0.112	NS
Total Cholesterol (mg/dl)	0.056	NS	0.077	NS
High sensitive CRP (mg/dl)	0.063	NS	0.067	NS
Hemodynamic factors				
Systolic Blood Pressure (mm Hg)	0.128	NS	0.289	0.04
Diastolic Blood Pressure (mm Hg)	0.319	0.004	0.598	<0.001
Heart rate	0.088	NS	0.022	NS
Left ventricular thickness				
LVPWd(cm)	0.155	NS	0.424	<0.001
IVSs (cm)	0.134	NS	0.114	NS
IVSd (cm)	0.394	<0.001	0.495	<0.001
LVPWs (cm)	0.451	<0.001	0.456	<0.001
LVPWt (cm)	0.435	<0.001	0.544	<0.001
LV mass index (gr/m ²)	0.383	0.0019	0.649	<0.001
Left ventricular systolic function				
Ejection fraction (%)	0.043	NS	0.297	0.021
Fractional shortening (%)	0.015	NS	0.025	NS
Left ventricular diastolic function				
Diastolic early wave peak velocity (cm/sn)	0.021	NS	0.040	NS
Diastolic late wave peak velocity (cm/sn)	0.028	NS	0.024	NS
E/A'	0.012	NS	0.021	NS
Acceleration time (ms)	0.305	0.034	0.279	0.045
Deceleration time (ms)	0.059	NS	0.044	NS
Left ventricular systolic and diastolic function				
Myocardial performance index	0.033	NS	0.288	0.042
Indicators of early atherosclerosis				
Carotid IMT (mm)	0.299	0.029	0.325	0.003
EATT (mm)	0.233	NS	0.339	0.022

Table 3: Relationships between NT-proBNP and cardiovascular factors and echocardiographic findings in obese adolescents.

BMI: Body Mass Index; EATT: Epicardial Adipose Tissue Thickness; HDL-C: High Density Lipoprotein - Cholesterol; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; LDL-C: Low Density Lipoprotein Cholesterol; LV: Left Ventricular; LVPWd: Left Ventricular Posterior Wall diastolic thickness; LVPWs: Left Ventricular Posterior Wall systolic thickness; LVPWt: Left Ventricular Posterior Wall thickness; IV: Interventricular; IVSs: Interventricular Septum systolic thickness; IVSd: Interventricular Septum diastolic thickness

	Obese		
	Hypertensive	Normotensive	p
n	34	104	
NT-proBNP (pg/ml)	86.5 ± 39.7	63.2 ± 44.4	0.023
Left ventricular mass index (gr/m ²)	78.5 ± 27.0	68.4 ± 16.8	0.042
Myocardial performance index	0.42 ± 0.1	0.40 ± 0.1	0.860
Carotid intima-media thicknesses (mm)	0.88 ± 0.2	0.71 ± 0.13	0.012
Epicardial adipose tissue thicknesses(mm)	7.12 ± 1.45	7.28 ± 1.56	0.980

Table 4: Comparison of the plasma N-terminal pro B-type natriuretic peptide levels, left ventricular mass index values, myocardial performance index, carotid intima-media, and epicardial adipose tissue thicknesses in obese subjects with normal and elevated blood pressures.

associated with higher concentrations of NT-pro-BNP, however; we did not find a significant correlation between insulin levels, insulin sensitivity markers and NT-pro-BNP levels.

In adult studies, the EATT was significantly correlated with the severity of coronary artery stenosis for patients with the known coronary artery disease [31]. Obesity seems to be a predisposing factor for the accumulation of excessive epicardial fat, however; we found no significant correlation between EATT and BMI in our study. Carotid IMT measurement is widely used method in the early diagnosis of atherosclerosis [32]. Di Salvo et al., [33] showed that carotid IMT was not greater in obese children than in nonobese control children. Iannuzzi et al., [34] reported that carotid IMT was increased in children with metabolic syndrome, but that this increase was not statistically significant. Numerous studies have shown that carotid IMT was increased in obese children and it is widely agreed that this increase in childhood is related to atherosclerosis in adulthood [35,36]. In our study, the carotid IMT measurements were significantly increased in the obese group compared to the control group. In addition to the study, a statistically significant correlation was found between EATT and carotid IMT. It is shown that the EATT is associated with atherosclerosis.

Natriuretic peptide hormones are very important for the maintenance of extracellular fluid volume within a narrow range despite wide variations in dietary sodium intake. The primary stimulus for natriuretic peptide release is myocyte stretching. Plasma levels of BNP and NT-proBNP are elevated in adult patients with a wide range of heart diseases including LV systolic and diastolic dysfunction. Thus, they serve as markers for heart disease [37]. Increased NT-proBNP levels were found to be closely related to cardiac structure and function and to be a strong independent indicator for long-term outcome in obese patients. In adult studies, increased serum NT-proBNP levels were found in cases with LV systolic and diastolic dysfunction [38,39]. Kim et al., [40] studied adults with hypertrophic cardiomyopathy and found a positive correlation of the serum NT-proBNP levels with the end-diastolic thickness of the interventricular septum and LV mass index. In this study, NT-proBNP levels were found to be significantly higher in obese adolescent than healthy controls and its levels were higher in obese cases with asymptomatic cardiac dysfunction than in normal control subjects. To the best of our knowledge, serum NT-proBNP levels in obese children have been previously reported in two different studies to date regardless of the presence of systolic and/or diastolic dysfunction. Saritas et al., [23] showed that NT-proBNP was greater in obese children than in nonobese control children but they reported

no correlations between the serum NT-proBNP levels and the body weight, carotid IMT, EATT, systolic and diastolic blood pressures, LV mass index and MPI values. Contrary to the this study performed with children, we detected statistically significant correlations between the serum NT-proBNP and BMI, blood pressure, LV mass index, carotid IMT and EATT in severely obese adolescent compared with non-obese and control adolescents. The other pediatric study, NT-proBNP levels in obese children were not different from healthy controls [41]. Similar to the studies in adults, statistically significant correlations were detected between the mitral annular MPI values and serum NT-proBNP levels in obese adolescent compared with nonobese control [42].

In adult studies, statistically significant positive correlations have been reported between the serum NT-proBNP and blood pressure and/or LV hypertrophy [9]. In children, NT-proBNP concentrations were found to be lower in the obese than the normal BMI group but higher in the obese hypertensive than the obese normotensive group [43]. In another pediatric study, NT-proBNP levels in hypertensive obese children were not different from non-hypertensive [23]. In this study, the average serum N-terminal pro B-type natriuretic peptide levels, average LVMI and carotid IMT were found to be significantly higher in the hypertensive obese adolescent than the non-hypertensive obese group.

Conclusion

Consequently, cardiac structural and functional changes affect systolic and diastolic functions in obese adolescents and increase the serum NT-proBNP values positive correlated with the LV mass index, MPI, EATT, and carotid IMT in obese adolescents. The LV mass index computed with the Doppler and tissue Doppler methods can be an important parameter for the early detection of cardiac dysfunction in obese adolescents. Measurements of the serum NT-proBNP levels might be related to elevation of especially diastolic dysfunction. Carotid IMT and EATT measurements in obese adolescent may be useful in predicting atherosclerosis in adulthood. In our study, a significant positive correlation was found between NT-proBNP and carotid IMT and EATT in severely obese cases. Thus high NT-proBNP level may be a risk factor in the predicting atherosclerosis in adulthood.

Summary points

- Childhood obesity is accompanied with an increased cardiovascular disease risk profile in adulthood
- N-Terminal-pro-Brain Natriuretic Peptide (NT-proBNP) is useful for the diagnosis of heart failure, and their high levels in serum and plasma, respectively, are related to wall stress, which is often increased in severely obesity.
- In this study, serum NT-proBNP levels were found to be significantly higher in obese children than in the control group.
- In this study; we determined statistically significant correlations between the serum NT-proBNP and BMI, blood pressure, LV mass index, carotid IMT and EATT in severely obese adolescents compared with non-obese control adolescents.

References

1. de Simone G, Devereux RB, Wallerson DC (1994) Echocardiographic assessment of left ventricular hypertrophy in rats using a simplified approach. *Am J Hypertens* 7: 555-558.
2. Eckel RH, Barouch WW, Ershow AG (2002) Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesity-associated cardiovascular disease. *Circulation* 105: 2923-2928.
3. Fernandes VR, Polak JF, Edvardsen T, Carvalho B, Gomes A, et al. (2006) Subclinical atherosclerosis and incipient regional myocardial dysfunction in asymptomatic individuals: the Multi-Ethnic Study of Atherosclerosis (MESA). *J Am Coll Cardiol* 47: 2420-2428.
4. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, et al. (2002) Obesity and the risk of heart failure. *N Engl J Med* 347: 305-313.
5. Alpert MA, Terry BE, Kelly DL (1985) Effect of weight loss on cardiac chamber size, wall thickness and left ventricular function in morbid obesity. *Am J Cardiol* 55: 783-786.
6. Smith HL, Willius FA (1933) Adiposity of the heart. *Arch Intern Med* 52: 911-931.
7. Nakajima T, Fujioka S, Tokunaga K, Hirobe K, Matsuzawa Y, et al. (1985) Noninvasive study of left ventricular performance in obese patients: influence of duration of obesity. *Circulation* 71: 481-486.
8. Alpert MA, Lambert CR, Panayiotou H, Terry BE, Cohen MV, et al. (1995) Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. *Am J Cardiol* 76: 1194-1197.
9. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, et al. (2004) N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. *J Hypertens* 22: 1597-1604.
10. Schirmer H, Omland T (1999) Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population. *The Tromsø Study. Eur Heart J* 20: 755-763.
11. Nasser N, Perles Z, Rein AJ, Nir A (2006) NT-proBNP as a marker for persistent cardiac disease in children with history of dilated cardiomyopathy and myocarditis. *Pediatr Cardiol* 27: 87-90.
12. Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA (2004) Use of NT-proBNP in routine testing and comparison to BNP. *Eur J Heart Fail* 6: 289-293.
13. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH (2000) Establishing a standard definition for child overweight and obesity worldwide: international survey. *BMJ* 320: 1240-1243.
14. Sen Y, Kandemir N, Alikasifoglu A, Gonc N, Ozon A (2008) Prevalence and risk factors of metabolic syndrome in obese children and adolescents: the role of the severity of obesity. *Eur J Pediatr* 167: 1183-1189.
15. Hatipoglu N, Ozturk A, Mazicioglu MM, Kurtoglu S, Seyhan S, et al. (2008) Waist circumference percentiles for 7- to 17-year-old Turkish children and adolescents. *Eur J Pediatr* 167: 383-389.
16. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics* 114: 555-556.
17. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C (2005) Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. *Pediatrics* 115: 500-503.
18. Sahn DJ, DeMaria A, Kisslo J, Weyman A (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. *Circulation* 58: 1072-1083.
19. Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G, et al. (2003) Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. *Obes Res* 11: 304-310.

20. Iacobellis G, Ribaudo MC, Assael F, Vecchi E, Tiberti C, et al. (2003) Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. *J Clin Endocrinol Metab* 88: 5163-5168.
21. Tounian P, Aggoun Y, Dubern B, Varille V, Guy-Grand B, et al. (2001) Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. *Lancet* 358: 1400-1404.
22. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, et al. (2007) Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. *Cerebrovasc Dis* 23: 75-80.
23. Saritas T, Tascilar E, Abaci A, Yozgat Y, Dogan M, et al. (2010) Importance of plasma N-terminal pro B-type natriuretic peptide, epicardial adipose tissue, and carotid intima-media thicknesses in asymptomatic obese children. *Pediatr Cardiol* 31:792-799.
24. Alpert MA (2001) Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. *Am J Med Sci* 321: 225-236.
25. Peterson LR, Waggoner AD, Schechtman KB, Meyer T, Gropler RJ, et al. (2004) Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. *J Am Coll Cardiol* 43: 1399-1404.
26. Wong C, Marwick TH (2007) Alterations in myocardial characteristics associated with obesity: detection, mechanisms, and implications. *Trends Cardiovasc Med* 17: 1-5.
27. Harada K, Orino T, Takada G (2001) Body mass index can predict left ventricular diastolic filling in asymptomatic obese children. *Pediatr Cardiol* 22: 273-278.
28. Sharpe JA, Naylor LH, Jones TW, Davis EA, O'Driscoll G, et al. (2006) Impact of obesity on diastolic function in subjects < or = 16 years of age. *Am J Cardiol* 98: 691-693.
29. Neeland IJ, Winders BR, Ayers CR, Das SR, Chang AY, et al. (2013) Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile. *J Am Coll Cardiol* 62: 752-760.
30. Bradham WS, Ormseth MJ, Oeser A, Solus JF, Gebretsadik T, et al. (2014) Insulin resistance is associated with increased concentrations of NT-proBNP in rheumatoid arthritis: IL-6 as a potential mediator. *Inflammation* 37: 801-808.
31. Jeong JW, Jeong MH, Yun KH, Oh SK, Park EM, et al. (2007) Echocardiographic epicardial fat thickness and coronary artery disease. *Circ J* 71: 536-539.
32. Charakida M, Tousoulis D, Stefanadis C (2006) Early atherosclerosis in childhood: diagnostic approaches and therapeutic strategies. *Int J Cardiol* 109: 152-159.
33. Di Salvo G, Pacileo G, Del Giudice EM, Natale F, Limongelli G, et al. (2006) Abnormal myocardial deformation properties in obese, nonhypertensive children: an ambulatory blood pressure monitoring, standard echocardiographic, and strain rate imaging study. *Eur Heart J* 27: 2689-2695.
34. Iannuzzi A, Licenziati MR, Acampora C, Salvatore V, Auriemma L, et al. (2004) Increased carotid intima-media thickness and stiffness in obese children. *Diabetes Care* 27: 2506-2508.
35. Atabek ME, Pirgon O, Kivrak AS (2007) Evidence for association between insulin resistance and premature carotid atherosclerosis in childhood obesity. *Pediatr Res* 61: 345-349.
36. Beauloye V, Zech F, Tran HT, Clapuyt P, Maes M, et al. (2007) Determinants of early atherosclerosis in obese children and adolescents. *J Clin Endocrinol Metab* 92: 3025-3032.
37. Mair J, Hammerer-Lercher A, Puschendorf B (2001) The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. *Clin Chem Lab Med* 39: 571-588.
38. Dong SJ, de las Fuentes L, Brown AL, Waggoner AD, Ewald GA, et al. (2006) N-terminal pro B-type natriuretic peptide levels: correlation with echocardiographically determined left ventricular diastolic function in an ambulatory cohort. *J Am Soc Echocardiogr* 19: 1017-1025.
39. Tschöpe C, Kasner M, Westermann D, Gaub R, Poller WC, et al. (2005) The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. *Eur Heart J* 26: 2277-2284.
40. Kim SW, Park SW, Lim SH, Kwon SU, Choi YJ, et al. (2006) Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction. *Clin Cardiol* 29: 155-160.
41. Battal F, Ermis B, Aktop Z, Can M, Demirel F (2011) Early cardiac abnormalities and serum N-terminal pro B-type natriuretic peptide levels in obese children. *J Pediatr Endocrinol Metab* 24: 723-726.
42. Miclăuș S, Mornoș C, Maximov D, Lupu A, Popa D, et al. (2009) [The myocardial performance index (Tei-Index): correlation with seric NTproBNP levels in patients with dilated cardiomyopathy]. *Rev Med Chir Soc Med Nat Iasi* 113: 391-396.
43. Pervanidou P, Akalestos A, Sakka S, Kanaka-Gantenbein C, Papassotiriou I, et al. (2010) Gender dimorphic associations between N-terminal pro-brain natriuretic peptide, body mass index and blood pressure in children and adolescents. *Horm Res Paediatr* 73: 341-348.